Neuroscientific Biopharmaceuticals Ltd (NSB) — Financial Flexibility Index
Neuroscientific Biopharmaceuticals Ltd (NSB) has a Financial Flexibility Index of -3.22x as of June 2025. Free cash flow of AU$-480.55K (operating CF AU$-480.55K minus capex AU$0.00) represents -3% of total liabilities (AU$149.22K). Check cash flow reinvestment rate of Neuroscientific Biopharmaceuticals Ltd to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Neuroscientific Biopharmaceuticals Ltd Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Neuroscientific Biopharmaceuticals Ltd across 10 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Neuroscientific Biopharmaceuticals Ltd.
Annual Financial Flexibility Index for Neuroscientific Biopharmaceuticals Ltd (2016–2025)
Year-by-year free cash flow to debt coverage for Neuroscientific Biopharmaceuticals Ltd. Explore Neuroscientific Biopharmaceuticals Ltd (NSB) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (AUD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -6.31x | AU$-941.33K | AU$-941.33K | AU$149.22K | ▼ -1273.4% |
| 2024 | 0.54x | AU$46.06K | AU$44.25K | AU$85.68K | ▲ +113.9% |
| 2023 | -3.86x | AU$-2.30 Million | AU$-2.30 Million | AU$597.36K | ▼ -23.3% |
| 2022 | -3.13x | AU$-6.94 Million | AU$-6.94 Million | AU$2.22 Million | ▲ +72.8% |
| 2021 | -11.51x | AU$-2.57 Million | AU$-2.60 Million | AU$223.41K | ▲ +55.3% |
| 2020 | -25.74x | AU$-2.28 Million | AU$-2.28 Million | AU$88.53K | ▼ -15.8% |
| 2019 | -22.22x | AU$-1.39 Million | AU$-1.41 Million | AU$62.48K | ▼ -254.5% |
| 2018 | -6.27x | AU$-478.83K | AU$-497.91K | AU$76.39K | ▼ -57.8% |
| 2017 | -3.97x | AU$-171.42K | AU$-186.42K | AU$43.15K | ▼ -523.9% |
| 2016 | -0.64x | AU$-77.76K | AU$-87.76K | AU$122.12K | — |